4.2 Review

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder

期刊

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
卷 14, 期 3, 页码 154-219

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/15622975.2013.770551

关键词

Bipolar disorder; Maintenance; Prophylaxis; Pharmacotherapy; Antipsychotics

资金

  1. Astra Zeneca
  2. BMS
  3. Desitin
  4. Eli Lilly
  5. Gedeon-Richter
  6. Hoffmann-LaRoche
  7. Janssen-Cilag
  8. Lundbeck
  9. Merck
  10. Otsuka
  11. Sanofi-Aventis
  12. Servier
  13. Sepracor
  14. UBC
  15. Bristol-Myers Squibb
  16. Forest Research Institute
  17. Gedeon Richter
  18. Glaxo-Smith-Kline
  19. Janssen
  20. Jazz
  21. Johnson Johnson
  22. Merck-Sharp and Dohme
  23. Novartis
  24. Pfizer Inc
  25. Roche
  26. Shering-Plough
  27. Solvay
  28. Takeda
  29. Teva
  30. Bristol Myers-Squibb
  31. Organon
  32. Boehringer-Ingelheim
  33. Cephalon/Teva
  34. Eisai
  35. P1Vital
  36. GSK
  37. Sunovion
  38. National Institute of Mental Health
  39. Janssen Cilag
  40. Pfizer
  41. Sanofi
  42. Schering-Plough
  43. Schwabe
  44. Wyeth
  45. German Science Foundation
  46. German Ministry of Science
  47. German Ministry of Health

向作者/读者索取更多资源

Objectives. These guidelines are based on a first edition that was published in 2004, and have been edited and updated with the available scientific evidence up to October 2012. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the long-term treatment of bipolar disorder in adults. Methods. Material used for these guidelines are based on a systematic literature search using various data bases. Their scientific rigor was categorised into six levels of evidence (A-F) and different grades of recommendation to ensure practicability were assigned. Results. Maintenance trial designs are complex and changed fundamentally over time; thus, it is not possible to give an overall recommendation for long-term treatment. Different scenarios have to be examined separately: Prevention of mania, depression, or an episode of any polarity, both in acute responders and in patients treated de novo. Treatment might differ in Bipolar II patients or Rapid cyclers, as well as in special subpopulations. We identified several medications preventive against new manic episodes, whereas the current state of research into the prevention of new depressive episodes is less satisfactory. Lithium continues to be the substance with the broadest base of evidence across treatment scenarios. Conclusions. Although major advances have been made since the first edition of this guideline in 2004, there are still areas of uncertainty, especially the prevention of depressive episodes and optimal long-term treatment of Bipolar II patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据